Blood Transfusion Devices Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Apheresis Systems, Infusion Devices, Blood Warmers, Venous Access Devices, Filters, Others), By End Use (Hospital, Ambulatory Surgical Centers, Dialysis Centers, Blood Bank, Others), By Region and Competition, 2020-2030F

Market Overview

Global Blood Transfusion Devices Market was valued at USD 4.80 Billion in 2024 and is expected to reach USD 6.61 Billion by 2030 with a CAGR of 5.68%. Blood transfusion devices, including blood bags, transfusion filters, apheresis equipment, and infusion pumps, play a critical role in maintaining the safety and efficiency of blood collection, processing, and administration. One of the primary factors fueling market expansion is the growing prevalence of conditions such as anemia, cancer, hemophilia, and kidney disorders, which often require repeated blood transfusions.

Additionally, the rise in emergency medical cases, including accidents and childbirth-related complications, is further contributing to the sustained demand for blood transfusion services, particularly in developing countries with expanding healthcare infrastructures. Despite these challenges, the global blood transfusion devices market is poised for sustained growth. Continued investment in technology, growing healthcare expenditure, and the increasing prioritization of patient safety are expected to drive further adoption of advanced transfusion solutions across both developed and emerging healthcare markets.

Key Market Drivers

Growth in Healthcare Industry

The robust expansion of the global healthcare industry stands as a primary driver of the blood transfusion devices market. The global healthcare industry generates annual revenues exceeding USD 4 trillion. Among its most substantial and lucrative segments are pharmaceuticals and biotechnology, contributing nearly USD 850 billion, followed by medical technology and diagnostics, which account for over USD 400 billion. As healthcare systems continue to evolve and expand to meet the growing needs of aging populations, rising surgical volumes, and the increasing prevalence of chronic and trauma-related conditions, the demand for safe and efficient blood transfusion practices has surged significantly. This, in turn, is fueling sustained investment in transfusion technologies, devices, and infrastructure.

A key aspect of this growth is the rising number of medical procedures including complex surgeries, organ transplants, chemotherapy, and emergency care all of which rely heavily on blood components such as red cells, plasma, and platelets. Out of the 313 million medical procedures performed globally each year, merely 6% take place in the poorest countries, which are home to more than one-third of the world’s population. These low surgical volumes correlate with elevated case-fatality rates for common, yet treatable, surgical conditions. The highest unmet demand is observed in Eastern, Western, and Central Sub-Saharan Africa, as well as South Asia. As more hospitals, clinics, and specialty care centers are established across both developed and emerging markets, there is a corresponding increase in the demand for advanced blood collection, storage, and transfusion equipment to support life-saving treatments.

Surge in Technological Advancements

The surge in technological advancements has become a pivotal driver of growth in the global blood transfusion devices market, reshaping how blood collection, storage, processing, and transfusion are managed across healthcare systems. HemoSep is engineered to recover blood lost during open-heart and major trauma surgeries by concentrating blood cells for reinfusion into the patient. This autotransfusion process minimizes the reliance on donor blood and mitigates complications related to transfusion reactions. These innovations are enhancing the safety, efficiency, and precision of transfusion procedures, thereby addressing long-standing challenges such as contamination risk, blood wastage, and procedural inefficiencies.

One of the most transformative developments is the integration of automated and digital blood management systems. Modern blood transfusion devices are now equipped with barcode scanning, RFID tracking, and real-time monitoring features that streamline donor-to-recipient traceability, reduce human error, and optimize inventory management in blood banks and hospitals. These technologies ensure accurate patient matching and improve compliance with stringent transfusion protocols, thereby minimizing the risk of transfusion-related complications.

Download Free Sample Report

Key Market Challenges

High Capital and Operational Costs

High capital and operational costs represent a substantial challenge to the growth and accessibility of the global blood transfusion devices market. While technological advancements have improved the precision, safety, and efficiency of blood transfusion procedures, they have also contributed to escalating costs associated with equipment acquisition, maintenance, and facility operations.

The initial capital investment required for setting up advanced blood transfusion infrastructure including apheresis machines, automated blood processing systems, and cold chain storage units is considerable. For hospitals and blood banks, particularly in low- and middle-income countries, these expenses can be prohibitive. The cost burden often limits the adoption of state-of-the-art technologies, creating disparities in the availability of safe and effective transfusion services across regions.

Key Market Trends

Expansion of Decentralized Blood Collection Models

The shift toward decentralized blood collection models has emerged as a notable trend shaping the global blood transfusion devices market. In response to growing demand for accessible, timely, and resilient blood supply systems, healthcare providers and governments are increasingly adopting decentralized frameworks that distribute blood collection activities across multiple community-based sites, mobile units, and rural healthcare centers, rather than relying solely on centralized facilities. Touch Activated Phlebotomy (TAP) devices enhance the accessibility of decentralized clinical trials by facilitating the convenient and reliable collection of up to 900µL of high-quality whole capillary blood. These devices support both remote and clinical use, eliminating the need for trained phlebotomists or painful fingerstick procedures.

This model is gaining momentum due to its ability to enhance donor outreach, improve regional blood availability, and strengthen emergency preparedness. By situating collection points closer to donors and patients, decentralized systems help bridge geographic gaps, especially in underserved or remote areas where access to centralized blood banks is limited. This approach is particularly valuable in managing regional disparities in blood donation and ensuring a steady supply for critical care, trauma management, and surgical procedures.

Segmental Insights

Product Insights

Based on Product, Apheresis Systems have emerged as the fastest growing segment in the Global Blood Transfusion Devices Market in 2024. This is due to their advanced functionality, growing clinical applications, and ability to deliver targeted therapeutic benefits. Unlike traditional blood transfusion methods that involve whole blood collection and separation, apheresis enables the selective extraction of specific blood components such as plasma, platelets, leukocytes, or red blood cells directly from the donor or patient, offering greater efficiency and precision in transfusion and treatment protocols. A key factor driving the rapid growth of this segment is the expanding use of apheresis in therapeutic applications. It plays a critical role in the management of various medical conditions including autoimmune diseases, hematologic disorders, neurological conditions, and certain cancers.

End Use Insights

Based on End Use, Hospital have emerged as the fastest growing segment in the Global Blood Transfusion Devices Market during the forecast period. This is due to their central role in managing high-volume, complex medical procedures that require reliable blood supply and advanced transfusion technologies. As primary centers for trauma care, surgical interventions, cancer treatments, and obstetric emergencies, hospitals consistently account for a substantial share of blood usage worldwide. Additionally, hospitals are more likely to have the infrastructure, trained personnel, and regulatory oversight required to adopt cutting-edge transfusion technologies and adhere to stringent quality standards.

Download Free Sample Report

Regional Insights

Based on Region, North America have emerged as the dominating region in the Global Blood Transfusion Devices Market in 2024. This is due to its advanced healthcare infrastructure, strong regulatory oversight, and high demand for sophisticated medical technologies. The region benefits from a well-established network of hospitals, blood banks, and diagnostic laboratories, which are equipped with the latest transfusion technologies and automated systems, thereby driving consistent adoption of cutting-edge blood collection, storage, and delivery devices. Moreover, the region maintains stringent regulatory standards enforced by agencies like the U.S. Food and Drug Administration (FDA) and Health Canada, which ensures the quality, safety, and efficacy of transfusion-related products. This regulatory rigor, combined with robust surveillance mechanisms, enhances confidence in transfusion procedures and accelerates the market penetration of high-performance devices.

Recent Development

• In April 2024, BD (Becton, Dickinson and Company) introduced the BD Vacutainer UltraTouch Push Button Blood Collection Set in India, aiming to reduce patient discomfort and enhance single-prick success during blood collection. The device incorporates BD RightGauge technology, which allows for the use of a finer needle, and is further enhanced by BD PentaPoint Technology to significantly minimize insertion pain. Additionally, the BD Push Button Technology integrated into the UltraTouch set is designed to lower the risk of needlestick injuries by up to 88%.
• In February 2025, Tasso, Inc., a leading provider of patient-centric, clinical-grade blood collection solutions announced the launch of its next-generation dried blood spot (DBS) sample collection technology. This innovative system integrates the new Tile-T20 dried whole blood cartridge with the Tasso Mini device, offering a streamlined and precise solution for DBS sample collection in clinical trials and sports anti-doping programs. The advanced collection system delivers significant improvements over traditional DBS methods, enhancing efficiency and reliability in clinical research. Notably, the Tile-T20 is the first DBS cartridge specifically engineered for use with patient-centric blood lancets and enables the collection of four accurately volumetrically-controlled samples, supporting the demands of quantitative endpoint analysis and drug concentration monitoring.
• In October 2024, Terumo Blood and Cell Technologies (Terumo BCT), a global leader in blood management solutions, introduced the Reveos Automated Blood Processing System in the United States to support blood centers in addressing supply demands for blood and platelets while enhancing operational efficiency. Carter BloodCare in Texas is preparing to adopt the Reveos system to produce platelets, red blood cells, and plasma for transfusion purposes. Reveos is the first whole blood automation device available in the U.S. capable of separating whole blood into three components platelets, plasma, and red blood cells in a single centrifugation cycle. This integrated approach optimizes the yield from whole blood donations and provides an effective solution to ongoing platelet shortages and the need for more streamlined blood processing workflows.
• In May 2024, Thermo Fisher Scientific Inc. launched the Applied Biosystems Axiom BloodGenomiX Array and Software, a comprehensive solution designed to identify a wide range of extended and rare blood groups, as well as tissue (HLA) and platelet (HPA) types, through a single high-throughput assay. This innovation is set to enhance future capabilities in donor blood matching for complex phenotypes. The Axiom BloodGenomiX Array analyzes over 40 genes and 260 antigens spanning 38 blood group systems, along with HLA and HPA markers. The product was developed in collaboration with the Blood Transfusion Genomics Consortium (BGC), a global alliance of blood services, research institutions, and industry stakeholders committed to advancing the safety and effectiveness of blood and platelet transfusion practices.

Key Market Players

• Immucor Inc.
• Becton Dickinson and Company
• B. Braun Melsungen AG
• Terumo Corporation
• Grifols SA
• Kaneka Corporation
• Fresenius Kabi AG
• Haemonetics Corporation
• Macopharma SA
• Ecomed Solutions, LLC.

Report Scope

In this report, the Global Blood Transfusion Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Blood Transfusion Devices Market, By Product:

o   Apheresis Systems

o   Infusion Devices

o   Blood Warmers

o   Venous Access Devices

o   Filters

o   Others

• Blood Transfusion Devices Market, By End Use:

o   Hospital

o   Ambulatory Surgical Centers

o   Dialysis Centers

o   Blood Bank

o   Others

• Blood Transfusion Devices Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Blood Transfusion Devices Market.

Available Customizations:

Global Blood Transfusion Devices Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Blood Transfusion Devices Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]